DGAP-News: Biotest AG / Key word(s): Preliminary Results
07.03.2019 / 09:00
The issuer is solely responsible for the content of this announcement.
Biotest increases operating result by EUR 20 million in 2018
– EBIT rises to EUR 10.6 million
– Sales grow by 5.9% to EUR 400.3 million
– Biotest meets sales and EBIT forecast
Dreieich, 07 March 2019. According to preliminary and unaudited figures, the Biotest Group increased sales in its continuing operations to EUR 400.3 million in the 2018 financial year. This corresponds to an increase of 5.9% over the previous year (EUR 378.1 million).
EBIT from continuing operations amounted to EUR 10.6 million in 2018 despite expenses of more than EUR 50 million for the “Biotest Next Level” expansion project. The previous year’s EBIT in the amount of -9.3 million was burdened by the recall of a drug.
Revenues from discontinued operations amounted to EUR 6.0 million after EUR 163.1 million in the previous year.
The EBIT of the discontinued operation rose to EUR 194.1 million after
Biotest will publish the final figures for the fiscal year 2018 and the annual report on 28 March, 2019. The Annual General Meeting of Biotest AG will take place on 7 May 2019 in Frankfurt am Main.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
07.03.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|